Evidence mapPaperPMID 42368567Full record

ReviewActa pharmaceutica Sinica. B2026

Where and when to strike: Spatiotemporally controlled smart nanomedicines for precision antibacterial therapy.

Zhipeng Li, Yutong Li, Zhiyong Liao, Jianliang Shen

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhipeng LiZhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
Yutong LiCollege of Life and Environmental Science, Wenzhou University, Wenzhou 325001, China.
Zhiyong LiaoCollege of Life and Environmental Science, Wenzhou University, Wenzhou 325001, China.
Jianliang ShenZhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global rise of antimicrobial resistance calls for new therapeutic approaches that move beyond conventional broad-spectrum antibiotics toward precision-guided nanotherapeutics. This review examines how smart antibacterial nanomedicines achieve better therapeutic outcomes through two key control dimensions: Spatial precision (where) and temporal activation (when). We first discuss active targeting strategies that direct therapeutic payloads to infection sites while sparing healthy tissues. We then analyze microenvironment-responsive mechanisms that keep therapeutic agents inactive until they encounter specific pathological signals. Moving beyond a simple catalog of material properties, we propose a "Hierarchical Intelligence Framework" that organizes nanoparticles along a spectrum of increasing complexity-from basic ligand-guided systems to integrated, logic-responsive nanodevices operating through "Target-Trigger-Treat" protocols. By examining design principles and practical challenges in pharmaceutical development, this work outlines a path toward resistance-overcoming nanomedicines that may reshape infection management in the coming decades.

Indexed as

Active targetingAntimicrobial resistanceBiofilm eradicationHierarchical intelligence frameworkPrecision antibacterial therapySmart nanomedicineSpatiotemporal controlStimuli-responsive systems

Identifiers

PMID42368567
PMCPMC13304653

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.